A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-145) for the Treatment of Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

Trial Profile

A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-145) for the Treatment of Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Dec 2017

At a glance

  • Drugs LN 145 (Primary)
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Sponsors Iovance Biotherapeutics
  • Most Recent Events

    • 13 Dec 2017 According to an Iovance Biotherapeutics media release, the company anticipates reporting early data from this study in 2018.
    • 13 Dec 2017 According to an Iovance Biotherapeutics media release, the company has amended the protocol so that newly enrolled patients can be treated using TIL produced from the Gen 2 manufacturing process.
    • 13 Dec 2017 According to an Iovance Biotherapeutics media release, the trial has met the efficacy threshold for the first stage of the Simon's two stage design and will therefore continue to enroll patients to the full sample size of 47 per protocol.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top